logo
logo

Rafa Laboratories To Acquire A Significant Stake In Exceed Orphan And Expand Its International Capabilities In Medicines Addressing Rare Diseases

Aug 01, 2022•almost 3 years ago

Acquiring Company

Rafa

Acquired Company

ExCEEd

PharmaceuticalBiotechnologyHealth CareTherapeuticsBiotechnologyHealth Care

Description

Rafa Laboratories LTD. ("Rafa") and ExCEEd Orphan s.r.o ("ExCEEd") announced today a strategic collaboration for medicines addressing rare diseases in Central and Eastern Europe ("CEE") and Israel. Under the agreement, and as part of its strategy to become an international player, Rafa will invest in ExCEEd an undisclosed amount that shall enable it to strengthen its market access capabilities in the region and move closer to fulfilling its vision to become a leading player in this important mission of pioneering access to patients with rare diseases. Furthermore, the parties shall collaborate on bringing new medicines for rare diseases to both the CEE and Israel.

Company Information

Company

Rafa

About

Founded in 1937 and headquartered in Jerusalem, Israel, Rafa is among the leading pharmaceutical companies in Israel and a global player in emergency solutions – medical countermeasures, supplying auto-injectors for government agencies, military forces and civilian populations. Rafa's competencies span over the entire value chain from R&D and manufacturing by international standards (e.g. FDA, EMA) all the way through sales and marketing. With a proven track record of successful commercialization of niche and orphan products, Rafa has been privileged to nurture long-lasting alliances with leading innovative companies such as United Therapeutics, Helsinn, Zambon, Galderma, Dr. Falk and Mundipharma, in a variety of therapeutic areas including oncology, hematology, respiratory, gastroenterology, and dermatology. Rafa's controlling shareholder, FIMI Opportunity Funds, is the leading private equity fund in Israel with a track record of success spanning over 25 years and assets under management of $7b. Since its inception, FIMI's performance has been exceptional by both local and global standards after having completed close to 100 investments. https://www.rafa.co.il/en Evaluate Orphan Drug Report 2022 World Bank Open Data – total population 2021 EFPIA - The Pharmaceutical Industry in Figures, Key Data 2022 (not including CEE's non-EU countries) Photo - https://mma.prnewswire.com/media/1870095/ExCEEd_Orphan_Rafa.jpg

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed